Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
https://www.zacks.com/stock/news/2254013/alkermes-alks-alks-2680-betters-wakefulness-in-phase-ib-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254013
Apr 11, 2024 - Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
0
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
https://www.zacks.com/stock/news/2249176/axsome-axsm-begins-solriamfetol-binge-eating-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249176
Apr 02, 2024 - Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
0
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
https://www.zacks.com/stock/news/2247989/why-is-jazz-jazz-up-1-3-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2247989
Mar 29, 2024 - Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0